Clinical Trials Logo

Nystagmus, Acquired clinical trials

View clinical trials related to Nystagmus, Acquired.

Filter by:
  • None
  • Page 1

NCT ID: NCT05176015 Active, not recruiting - Stroke, Acute Clinical Trials

Nystagmus Assessment for Patients Consulting in the Emergency Department for Acute Vertigo

Start date: January 15, 2022
Phase: N/A
Study type: Interventional

This pilot study is perfomed to validate and document faisability of the use of Frenzel lens and the use of a diagnostic algorithm for the assessment of a special sign (nystagmus) observe in the eyes of patients consulting in the emergency department (ED) for an acute episode of vertigo/dizziness/imbalance.

NCT ID: NCT02189720 No longer available - Clinical trials for Congenital Myasthenic Syndrome

Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS),Congenital Myasthenic Syndrome

EAP-001
Start date: n/a
Phase:
Study type: Expanded Access

Primary: The primary objective of this study under the original protocol was to provide neuromuscular specialists and neurologists access to amifampridine phosphate therapy for their patients with LEMS, CMS or downbeat nystagmus until the product became commercially available. Secondary: The secondary objective of this study under the original protocol was to provide additional long-term safety data on amifampridine phosphate in patients. Primary The primary objective of this study after its fifth amendment was to provide access to amifampridine phosphate therapy to pediatric patients with LEMS, and pediatric and adult patients with CMS until the product became commercially available for these indications or development of the product for the indication was terminated. Secondary: The secondary objective of this study after its fifth amendment was to assess the long-term safety of amifampridine phosphate in pediatric patients with LEMS, and pediatric and adult patients with CMS.

NCT ID: NCT00799942 Terminated - Multiple Sclerosis Clinical Trials

Open-lable Extension Study on Safety and Efficacy of Neramexane to Treat Congenital and Acquired Nystagmus

Start date: May 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate the long-term safety, tolerability and efficacy of neramexane mesylate in the treatment of congenital idiopathic nystagmus (CIN). In addition, a subgroup of multiple sclerosis (MS) patients suffering from acquired nystagmus will be included.

NCT ID: NCT00661440 Completed - Nystagmus, Acquired Clinical Trials

Efficacy and Safety Study of Neramexane to Treat Congenital and Acquired Nystagmus

Start date: May 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate the safety and efficacy of neramexane mesylate in the treatment of congenital idiopathic nystagmus (CIN) in comparison to placebo. In addition, a subgroup of multiple sclerosis (MS) patients suffering from acquired nystagmus will be included; this subgroup will be analyzed in an exploratory manner only.